(Q39421840)

English

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

0 references

multicenter clinical trial

0 references

author name string

Elhilali MM

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ramsey EW

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Barkin J

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Casey RW

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Boake RC

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Beland G

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Fradet Y

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Trachtenberg J

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Orovan WL

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Schick E

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Klotz LH

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

1 March 1996

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

47

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

335-342

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The development of human benign prostatic hyperplasia with age

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical management of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Transurethral prostatectomy: practice aspects of the dominant operation in American urology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder Neck

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative analyses of human prostatic .ALPHA.-adrenoceptors and effects of terazosin on the .ALPHA.-adrenoceptor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A Placebo-controlled Double-blind Study of the Effect of Phenoxybenzamine in Benign Prostatic Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Prazosin in Patients with Benign Prostatic Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prazosin in the Treatment of Prostatic Obstruction A Placebo-controlled Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of terazosin in patients with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of terazosin on urine storage and voiding in the aging male with prostatism

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of once-A-day terazosin in benign prostatic hyperplasia: A randomized, double-blind placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of terazosin for the treatment of symptomatic BPH

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Terazosin in the treatment of benign prostatic hyperplasia: the United States experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980449-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(99)80449-X

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39421840&oldid=1826819025"